LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the discovery, research and clinical development of novel anti-cancer drug candidates that employ novel technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s LADR (Linker Activated Drug Release) technology platform consists of an organic backbone that is attached to a chemotoxic agent. The LADR backbone is to target and deliver the chemotoxic agent to the tumor environment and then to release the chemotoxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADR7, 8, 9, and 10, combine the proprietary LADR backbone with novel derivatives of the auristatin and maytansinoid drug classes.
LADXD - LadRx Corp
Report
There was a problem reporting this post.
Block Member?
Please confirm you want to block this member.
You will no longer be able to:
See blocked member's posts
Mention this member in posts
Please allow a few minutes for this process to complete.